Animal biotechnology is a branch of biotechnology in which molecular biology techniques are used to genetically engineer (i.e. modify the genome of) animals in order to improve their suitability ...
NCBiotech makes Fast Company's 2025 Most Innovative Companies list The North Carolina Biotechnology Center has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of ...
Free Expression: Judging by Democrats' reaction at USAID, the Treasury and the Department of Education, Elon Musk’s Department of Government Efficiency looks less DOGE and more DOGA, a ...
U.S. inflation data for February will be the highlight among economic data as investors continue to follow the back-and-forth of U.S. President Trump’s announcements on tariffs. A rate decision ...
A course delivered entirely in English, with an international approach, teaching the methods and instruments of biotechnology for the prevention, diagnosis and therapy of human diseases. You will deal ...
No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...
The deal sees Lilly pay out $9 million upfront plus another $1 million after 15 months to the San Diego biotech, according to Securities and Exchange Commission (SEC) documents filed Feb. 25.
In September, Akeso, a little-known Chinese biotech company founded nearly a decade ago shook up the biotech sector with its new lung cancer drug. Ivonescimab, the new drug, was found in a trial ...
Coronary artery disease (CAD), or the narrowing of the coronary arteries, is the leading cause of morbidity and mortality throughout the world. Atherosclerosis, or the buildup of plaque in the ...
Eikon Therapeutics, a well-funded drug startup run by Merck & Co.’s former research chief, has raised one of the biggest venture rounds for a biotechnology company so far this year. The company on ...
It’s no great surprise that RA Capital weighed in — again — as the most ubiquitous venture player in private biotech rounds through 2024. Or that ARCH … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback